Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claim 1 (currently amended) A compound of the formula I:

$$\mathbb{R}^{3}$$

$$\mathbb{R}^{3}$$

$$\mathbb{R}^{1}$$

$$\mathbb{R}^{1}$$

wherein:

R1 is

R2 is selected from the group consisting of:

- (1) $R^4-S(O)_m-NR^5-$,
- (2) $R^4-S(O)_{m^2}$
- (3) R^4NHCO- ,
- (4) R4CONH-,
- (5) $R^4R^5N_{-}$
- (6) nitrile,
- (7) NC-C1-salkyl-,
- (8) halogen,

(9)

$$R^{8a}$$
 R^{8b} , and

(10)

 ${\bf R}^3$ is selected from the group consisting of:

$$R^{6c}$$
 R^{6b}
 R^{6a}
 R^{6b}
 R^{6a}
 R^{6b}
 R^{6a}
 R^{6a}
 R^{6b}
 R^{6a}

 R^4 is selected from the group consisting of:

- (1) hydrogen,
- (2) C₁₋₆alkyl,
- (3) phenyl, and
- (4) benzyl;

 R^{5} is independently selected from the group consisting of:

- (1) hydrogen;
- (2) C₁₋₆alkyl,

- (3) phenyl,
- (4) benzyl, and

 R^{6a} , R^{6b} , and R^{6c} are independently selected from the group consisting of:

- (1) hydrogen,
- (2) halogen,
- (3) $-OR^5$,
- (4) -SR⁵, and
- (5) C₁₋₆alkyl;

R7 is selected from the group consisting of -C=C-, O, S, and NH;

Z is selected from the group consisting of CO, CH-OH, CH-F-and



 $\boldsymbol{R}^{\text{8a}}$ and $\boldsymbol{R}^{\text{8b}}$ are independently selected from the group consisting of:

- (1) nitrile
- (2) hydrogen,
- (3) halogen,
- (4) $-OR^5$,
- (5) $-SR^5$,
- (6) C₁₋₆alkyl,
- (7) $-CO_2R^5$, and
- (8) tetrazolyl;

X1 is hydrogen and X2 is hydroxyl; n is independently 1, 2, 3, or 4; m is independently 0, 1, or 2; and pharmaceutically acceptable salts thereof.

Claim 2 (Canceled)

Claim 3 (Canceled)

Claim 4 (Canceled)

Claim 5 (Canceled)

Claim 6 (currently amended) The compound of Claim 1 wherein:

R⁵ is hydrogen or methyl;

Z is selected from the group consisting of CO, CH OH, and



and pharmaceutically acceptable salts thereof.

Claim 7 (Original) The compound of Claim 1 wherein R2 is:

R4-S(O)2-NR5-

and wherein R4 is selected from the group consisting of:

- (1) hydrogen,
- (2) C₁₋₆alkyl,
- (3) phenyl, and
- (4) benzyl;

R⁵ is selected from the group consisting of:

- (1) C₁₋₆alkyl,
- (2) phenyl,
- (3) benzyl, and
- (4) hydrogen;

and pharmaceutically acceptable salts thereof.

Claim 8 (Original) The compound of Claim 1 wherein R3 is:

and wherein:

R4 is methyl;

R6a is H or F;

R6b and R6c are hydrogen;

and pharmaceutically acceptable salts thereof.

Claim 9 (Original) The compound of Claim 1 wherein R³ is:

wherein:

R⁵ is methyl;

R7 is O or NH;

and pharmaceutically acceptable salts thereof.

Claim 10 (Canceled).

Claim 11 (previously presented) The compound of Claim 3 which is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

Claim 12 (Original) A compound of Claim 1 in substantially diastereomerically pure form.

Claim 13 (Original) A substantially diastereomerically pure compound of Claim 1 in substantially enantiomerically pure form.

Claim 14 (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

Claim 15 (canceled)

Claim 16 (Cancelled)

Claim 17 (currently amended) A method for treating, preventing, controlling, ameliorating or reducing the risk of Alzheimers Alzheimer's disease in a patient comprising the administration to the patient of a therapeutically effective amount of a compound of Claim 1.